Aromatase inhibitors substantially reduce risk of death in ER-positive breast cancer
the ONA take:
According to a study published in the journal The Lancet, researchers have found that aromatase inhibitors significantly decrease the risk of death in postmenopausal women with estrogen receptor-positive breast cancer.
For the meta-analysis, researchers analyzed data from 31,920 postmenopausal women with estrogen receptor-positive early breast cancer. Researchers compared the impact of aromatase inhibitor treatment with tamoxifen treatment on breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality.
Results showed that aromatase inhibitors reduce recurrence rates by approximately 30% more than with tamoxifen. Researchers found that 5 years of aromatase inhibitor treatment decreases 10-year breast cancer mortality by about 15% more than with 5 years of tamoxifen, and by about 40% more compared with no endocrine treatment at all.
"Our global collaboration has revealed that the risk of postmenopausal women with the most common form of breast cancer dying of their disease is reduced by 40% by taking five years of an aromatase inhibitor - a significantly greater protection than that offered by tamoxifen," lead author Professor Mitch Dowsett, Head of the Academic Department of Biochemistry and of the Centre for Molecular Pathology at The Royal Marsden and The Institute of Cancer Research, London, said.
Aromatase inhibitors significantly decrease the risk of death in postmenopausal women with estrogen receptor-positive breast cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|